ISPC
iSpecimen Inc.
Set alert
- YTD
- -92.06%
- 1 year
- -97.34%
- Open
- 0.83
- Prev close
- 0.7923
- Mkt cap
- 2.08M
- Vol
- 543.34K
- Avg vol
- 708.69K
- EPS
- -52.98
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.753
- High
- 0.8699
- Forward P/E
- -3.54
- Beta
- 1.59
- Short ratio
- 0.08
- Inst. own
- 4.04%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 4.23
- 200-d avg
- 5.36
- 1y target
- 0.00
Key statistics
- Market cap
- 2.70M
- Enterprise value
- 2.19M
- Trailing P/E
- 0.00
- Forward P/E
- -3.54
- PEG ratio
- 0.00
- Price / sales
- 0.26
- Price / book
- 0.49
- EPS (TTM)
- -18.12
- Beta
- 1.59
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -91.66%
- Revenue (TTM)
- 10.39M
- Revenue growth
- -4.20%
- Free cash flow
- 0
- Total cash
- 1.75M
- Total debt
- 1.19M
- Return on equity
- -109.34%
- Shares outstanding
- 962.64K
- Short % of float
- 3.63%
- 50-day average
- 4.23
- 200-day average
- 5.36
Analyst view
Consensus: none
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 7, 2024 | Sep 1, 2024 | 0.00 | -2.10 | — | — |
| Aug 6, 2024 | Jun 1, 2024 | 0.00 | -3.80 | — | — |
| May 7, 2024 | Mar 1, 2024 | 0.00 | -6.40 | — | — |
| Mar 13, 2024 | Dec 1, 2023 | 0.00 | -6.80 | — | — |
| Nov 2, 2023 | Sep 1, 2023 | 0.00 | -4.60 | — | — |
| Aug 2, 2023 | Jun 1, 2023 | 0.00 | -7.80 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 23, 2022 | EF Hutton | main | — | Buy |
| Jan 4, 2022 | Craig-Hallum | init | — | Buy |
| Nov 22, 2021 | EF Hutton | main | — | Buy |
About iSpecimen Inc.
iSpecimen Inc. provides technology that connects life science researchers who need human biofluids, tissues, and living cells for their research with biospecimens available in healthcare provider organizations worldwide. Its cloud-based technology enables scientists to search for specimens and patients across a network of hospitals, clinics, private practice groups, laboratories, blood centers, biobanks, clinical research sites, and cadaveric donation centers. The company develops and operates iSpecimen Marketplace, a proprietary online marketplace platform that connects medical researchers who need access to subjects, samples, and data with hospitals, laboratories, and other organizations who have access to them. It serves biopharmaceutical companies, in vitro diagnostic companies, and government/academic institutions. iSpecimen Inc. was incorporated in 2009 and is headquartered in Lexington, Massachusetts.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Country
- United States
- Website
- ispecimen.com
News
- 12 Health Care Stocks Moving In Friday's Pre-Market Session
- 12 Health Care Stocks Moving In Thursday's After-Market Session
- iSpecimen Offers Next-Day Healthy Donor Blood and Launches Development of AI Agent
- 12 Health Care Stocks Moving In Thursday's Pre-Market Session
- 12 Health Care Stocks Moving In Thursday's After-Market Session
- iSpecimen Inc. (NASDAQ:ISPC) Stock Short Interest Rises 53.3%
- VivoSim Labs (NASDAQ:VIVS) vs. iSpecimen (NASDAQ:ISPC) Head to Head Comparison
- iSpecimen Supports Hospital Validation of New Chemistry Analyzer
- Stock Market Today: S&P 500, Dow, Nasdaq 100 Futures Fall as Oil Tops $99 Despite Trump’s Price Drop Prediction— ASML, NVS, CASY in Focus (UPDATED)
- 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Your note
Sign in to keep a note on ISPC — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BASILE JOSEPH J. | Director | Stock Award(Grant) | Dec 29, 2022 | 63 |
| BIELAK BENJAMIN | Chief Technology Officer | Purchase | Sep 13, 2023 | 84,348 |
| BROOKS JOHN L III | Director | Stock Award(Grant) | Dec 29, 2022 | 3,250 |
| CURLEY TRACY | Chief Executive Officer | Purchase | May 30, 2023 | 49,541 |
| GULLANS STEVEN R. PH.D | Director | Stock Award(Grant) | Dec 29, 2022 | 3,250 |
| IANELLI CHRISTOPHER | Director | Conversion of Exercise of derivative security | Jan 5, 2023 | 425,359 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Jane Street Group, LLC | 2.27% | 21,895 | 61.30K | Sep 29, 2024 |
| FNY Investment Advisers, LLC | 1.19% | 11,500 | 32.20K | Sep 29, 2024 |
| Blackrock Inc. | 0.29% | 2,827 | 7.92K | Sep 29, 2024 |
| UBS Group AG | 0.15% | 1,469 | 4.11K | Sep 29, 2024 |
| Tower Research Capital LLC (TRC) | 0.12% | 1,168 | 3.27K | Sep 29, 2024 |
| Bank of America Corporation | 0.01% | 59 | 165 | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 0.27% | 2,596 | 7.27K | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.19% | 1,800 | 5.04K | Sep 29, 2024 |
| Fidelity Total Market Index Fund | 0.12% | 1,176 | 3.29K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.10% | 945 | 2.65K | Oct 30, 2024 |
| Fidelity NASDAQ Composite Index Fund | 0.03% | 267 | 747 | Oct 30, 2024 |